Regen BioPharma Inc Information

Regen BioPharma, Inc. is a biotechnology company. The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space. The Company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc.

View Top Employees from Regen BioPharma Inc

Website	http://regenbiopharmainc.com
Ticker	RGBP
Revenue	$100000
Employees	View employees
Founded	2012
Address	4700 Spring St 304, La Mesa, California 91942, US
Phone	(619) 722-5505
Fax	(619) 330-2328
Technologies	JavaScript, HTML, Google Analytics +6 more (view full list)
Industry	Pharmaceutical Manufacturing, Business Services General, Biotechnology, Business Services, Science and Engineering
Competitors	Minerva Biotechnologies, Nutra Pharma Corporation, OxThera, ReGen Therapeutics Plc, Synthorx Inc
SIC	SIC Code 873 Companies, SIC Code 87 Companies, SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 32541 Companies